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Abstract: Background: Autosomal forms of Alport syndrome represent 20% of all patients (15% recessive and 5% 
dominant). They are caused by mutations in the COL4A3 and COL4A4 genes, which encode a-3 and a-4 collagen IV 
chains of the glomerular basement membrane, cochlea and eye. Thin basement membrane nephropathy may af-
fect up to 1% of the population. The pattern of inheritance in the 40% of cases is the same as autosomal dominant 
Alport syndrome: heterozygous mutations in these genes. The aim of this study is to detect new pathogenic muta-
tions in the COL4A4 gene in the patients previously diagnosed with autosomal Alport syndrome and thin basement 
membrane nephropathy in our hospital. Methods: We conducted a clinical and genetic study in eleven patients 
belonging to six unrelated families with aforementioned clinical symptoms and a negative study of COL4A3 gene. 
The molecular study was made by conformation of sensitive gel electrophoresis (CSGE) and direct sequencing of 
the fragments that show an altered electrophoretic migration pattern. Results: We found two pathogenic mutations, 
not yet described: IVS3 + 1G > C is a replacement of Guanine to Cytosine in position +1 of intron 3, in the splicing 
region, which leads to a pathogenic mutation. c.4267C > T; p.P1423S is a missense mutation, also considered 
pathogenic. We also found seven new polymorphisms. Conclusions: We describe two new pathogenic mutations, 
responsible for autosomal dominant Alport syndrome. The other families of the study were undiagnosed owing to 
problems in the method employed and the possibility of mutations in other genes, giving rise to other diseases with 
similar symptoms. 
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Introduction
Thin basement membrane nephropathy (TBMN) 
and Alport syndrome [1] are the two major clini-
cal entities associated with disorders of the 
glomerular basement membrane occurring 
with haematuria. TBMN affects up to 1% of the 
population and is defined by a thinning of the 
glomerular basement membrane associated 
with haematuria and minimal proteinuria, with 
normal kidney function. It is inherited in an 
autosomal dominant pattern [1, 2]. 
Alport syndrome (AS) is a hereditary nephropa-
thy characterized by progressive glomerulone-
phritis resulting in kidney failure, with typical 
ultrastructural changes in the glomerular base-
ment membrane and haematuria, which is 
often associated with sensorineural hearing 
loss and damage to the eye [2].
Both entities may be caused by mutations in 
COL4A3 or COL4A4 genes, which encode α3(IV) 
and α4(IV) collagen chains [3], which are pres-
ent in the glomerular basement membrane, the 
cochlea and the eye. Autosomal recessive 
Alport syndrome (ARAS) (15% of cases of AS) is 
a consequence of homozygous mutations in 
COL4A3 and COL4A4 gene, or a result of com-
pound heterozygous mutations in these genes. 
Autosomal dominant Alport syndrome (ADAS) 
and TBMN (5% of cases of AS) result from het-
erozygous mutations in these genes [4]. ARAS 
carriers and those affected by the dominant 
forms are included in the term “collagen type IV 
(α3-α4) nephropathy” [2]. 
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detect the possible mutations in these regions. 
Direct sequencing of the fragments that 
showed an altered electrophoretic migration 
pattern was performed in both directions, using 
an ABI 3100 Genetic Analyzer. Reading and 
processing of automatic sequences were per-
formed with the 4Peaks 1.7.2 (1.7.1) program 
for Mac OS X (http://www.mekentosj.com/
science/4peaks).
Results
We studied 11 patients, five males (45.5%) and 
six females (54.5%). Analysis of family trees 
(Figure 1) showed that seven patients (63.6%) 
had an autosomal dominant mode of inheri-
tance. Five of them had clinical ADAS (family 6) 
and the remaining two patients suffered from 
BHF (family 1). Three patients (27.3%) suffered 
from ARAS and had a history of consanguinity 
(family 2) and the last patient (9.1%) had no 
family history, so the mode of inheritance could 
not be determined. The median age of clinical 
diagnosis was 51.5 years (19.75 to 55.75). 
First family: The index patient was a 23-year-old 
woman who had an episode of microhematuria 
and proteinuria of 0.55 mg/24 h at the age of 
14, which remained stable. Since that time she 
suffered from sporadic episodes of microhema-
turia. There were no signs of arterial hyperten-
sion, impairment of renal function, hearing 
loss, lenticonus or macular flecks. The com-
plete kidney study and the renal biopsy did not 
reveal any conclusive results.
Her mother was a 48-year-old woman who was 
diagnosed with an isolated episode of microhe-
maturia at the age of 42. Any previous episodes 
had not been reported. She did not show arte-
rial hypertension, proteinuria, kidney failure or 
hearing or visual impairment. The maternal 
grandparents of the index case did not show 
any clinical symptom.
The main indication of the disease is haematu-
ria, but it can also cause proteinuria. The result 
is the development of chronic renal failure and 
end stage renal disease. The impairment of 
renal function is rapid and severe in both men 
and women with the recessive form, while 
symptoms for patients with ADAS may be mild-
er and more gradual, which means the kidney 
disease may only become apparent around the 
7th decade [5, 6].
We searched mutations in the COL4A4 gene in 
6 families who suffer from autosomal forms of 
the disease, which had no pathogenic muta-
tions in the COL4A3 gene. We describe seven, 
as yet unreported polymorphisms and two new 
pathogenic mutations in the COL4A4 gene 
associated with ADAS. 
Material and methods
Eleven patients who belonged to six unrelated 
families with clinical symptoms of ARAS or col-
lagen type IV (α3-α4) nephropathy were select-
ed. The clinical diagnosis of Alport syndrome 
was established when the index patient met at 
least two of the following criteria [7]: (1) Positive 
family history of macro or microscopic hematu-
ria with or without progression to end-stage 
chronic kidney disease; (2) Progressive sensori-
neural high tone hearing loss; (3) Characteristic 
ocular injuries (lenticonus or perimacular reti-
nopathy); (4) Compatible anatomopathological 
injuries.
The COL4A3 gene was previously analysed in 
all index patients and we did not find any patho-
genic mutation. We made a descriptive analysis 
of the clinical data of the families in order to 
determine the characteristics of disease pre-
sentation. Results are expressed as percent-
ages, median and interquartile range. The vari-
ables studied are listed in Tables 1, 2.
Molecular analysis
High molecular weight DNA was 
extracted from peripheral blood in 
all index patients. Coding regions 
and flanking intronic sequences of 
the COL4A4 gene were studied 
after amplification by polymerase 
chain reaction with Master Mix 
(Promega), under standard condi-
tions (Table S1). The samples 
obtained were analysed by hetero-
duplex with acrylamide gels to 
Table 1. Distribution and age of onset of symptoms studied
Clinical symotoms Number of patients Onset (years)
Chronic kidney disease 8 (72.7%) 39.5 (30-58, 25)
End-stage chronic kidney disease 4 (36.4%) 45.5 (24-52, 75)
Haematuria 10 (90.9%) 29 (8, 25-44)
Proteinuria 10 (90.9%) 39 (17, 5-56)
Hypertenson 8 (72.7%) 41.5 (23, 25-52, 25)
Hearing loss 8 (72.7%) 8 (5-61)
Macular flecks 1 (9.1%) 48 (48-48)
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Table 2. Distribution of the symptoms in each family
Family
                                                           Symotom 1 2 3 4 5 6
Hamaturia Yes Yes Yes Yes Yes Yes
Proteinuria No Yes Yes Yes Yes Yes
Chronic kidney disease No Yes Yes Yes Yes Yes
End-stage chronic kidney disease No Yes Yes No No Yes
Hearing loss No Yes Yes Yes Yes Yes
Macular flecks No No Yes No No No
Macrothrombcytopenia No No No Yes No No
Laminated glomerular basement membrane No Not studied Not studied Yes Not studied Yes
The personal and family record led us to sus-
pect TBMN, but we did not find any pathogenic 
mutation after sequencing 25 exons of the 
COL4A4 gene.
Second family: The index case was a 54-year-
old man. He had high tones sensorineural hear-
ing loss from the age of 5. At the age of 50, he 
suffered from arterial hypertension, microhe-
maturia and proteinuria of 1.9 g/24 h, with 
chronic kidney disease, which resulted in the 
need of dialysis two years later. No renal biopsy 
was performed because he suffered from 
severe kidney impairment at the beginning of 
clinical monitoring. He was never diagnosed 
with visual impairment.
The patient came from a family of 9 children 
and his parents were related.
The father had been deaf since childhood and 
suffered from chronic kidney disease, which did 
Figure 1. Genealogic trees of the studied families. Family 2 shows an autosomal recessive pattern of inheritance. 
The rest of them have an autosomal dominant one.
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not evolve to an end-stage one. The existence 
of hematuria, proteinuria or ocular injuries like 
lenticonus or macular flecks could not be 
studied.
The mother only suffered from type 2 dia- 
betes.
The eldest sister had suffered from high tones 
sensorineural hearing loss since childhood. 
She died at the age of 50 due to a cerebral 
hemorrhage. She did not have renal disorders, 
visual impairment or arterial hypertension.
The next three siblings, two males and one 
female, suffered from sensorineural hearing 
loss and died during childhood due to unknown 
causes. The fifth sister was a 68-year-old 
woman who had had arterial hypertension and 
type 2 diabetes mellitus since she was 53. At 
61 years old, she was diagnosed with high 
tones sensorineural hearing loss as well as 
chronic kidney disease, with creatinine clear-
ance around 50 ml/min, which remained stable 
since that time. At the age of 62, a urinalysis 
showed microscopic hematuria and proteinuria 
(0.2 g/24 h). She refused to undergo a renal 
biopsy. She did not suffer ocular impairment.
The eighth brother had had high tones sensori-
neural hearing loss from the age of 4. At 39, he 
was diagnosed with nephrotic range proteinuria 
(3.9 g/24 h), macroscopic hematuria and 
chronic kidney disease, which evolved to end-
stage kidney disease at the age of 53. It was 
then he started hemodialysis. He died two 
years later due to complications derived from 
the aforementioned kidney disease. He never 
suffered from hypertension or ocular injuries. 
The two remaining sisters did not show any sig-
nificant symptoms or abnormalities on testing.
The main symptom of the family was sensori-
neural hearing loss. However, we did not have 
any specific data regarding the continued devel-
opment of this condition as most of the patients 
died during childhood and the information was 
not included in their medical records.
The clinical and familiar data suggested the 
presence of ARAS, but no pathogenic mutation 
was found after sequencing 20 exons of the 
studied gene. 
Third family: The index case was a 49-year-old 
woman who, at the age of 6 was diagnosed with 
Figure 2. Genetic sequence of the c.4267C > T; p.P1423S mutation and the polypheny multiple sequence align-
ment, in which we can see the high degree of conservation of proline among different species. This fact leads us to 
think that the change of proline to serine could have a critical effect on the resulting protein.
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high tones sensorineural hearing loss, resulting 
in the current need for a hearing aid. When she 
was 28 she showed microhematuria, protein-
uria (0.5 g/24 h) and kidney disease (creatinine 
clearance of 40 ml/min). These symptoms were 
continuous from that time on.
She showed arterial hypertension at the age of 
47 and macular flecks at 48.
A renal biopsy was never performed due to the 
impaired kidney function at the beginning of 
the study. 
Her mother had been deaf from an early age, 
as well as suffering from stage III chronic kid-
ney disease, hematuria and proteinuria. Her 
brother was diagnosed with hematuria, protein-
uria and end-stage kidney disease of unknown 
origin since adolescence and died because of 
medical complications from this. He was never 
diagnosed with hearing loss or ocular injuries.
The index case’s daughter suffered from senso-
rineural hearing loss since childhood, probably 
with a congenital origin.
This data led us to suspect the existence of 
ADAS. We found the change c.4267C > T; p.
P1423S in exon 45 of the COL4A4 gene. This is 
a missense mutation that should be catego-
rised within unclassified variants, since it has 
not been previously described. We conducted a 
population-based study in 100 alleles using the 
CSGE technique and the mutation was not 
present in any of the healthy subjects. “In sili-
co” studies were also carried out to predict the 
behaviour of this mutation on the protein. 
Polyphen and 3D SNPs predicted the mutation 
to be pathogenic (score of 0.989 in Polyphen 
and -0.05 in 3D SNPs). SIFT program also con-
sidered it deleterious. The mutation is present 
in the index case, her mother and her daughter. 
We could not look for it in her brother owing to 
the fact that he had already died by the time of 
the research.
Fourth family: The index patient was a 51-year-
old woman who had her first episode of spo-
radic microhematuria at the age of 10. 
Thereafter, she was diagnosed with congenital 
sensorineural hearing loss. At the age of 21, 
she showed arterial hypertension and protein-
uria of 0.8 g/24 h, which increased progres-
sively until nephrotic range being, at the time of 
the study, around 7 g/24 h. The renal biopsy 
with electron microscopy study revealed a lami-
nated glomerular basement membrane. At this 
age the presence of macrothrombocytopenia 
was also observed. She had suffered from 
chronic kidney disease since the age of 40, 
with a creatinine clearance around 45 ml/min. 
She did not show any ocular impairment or a 
family history of AS symptoms.
This data led us to surmise that the patient 
was affected by ARAS or a sporadic mutation. 
We could not find any pathogenic mutation 
in COL4A4 gene (we sequenced 24 exons).
Fifth family: The index case was a 55-year-old 
man who was diagnosed with arterial hyperten-
sion and microhaematuria at the age of 30. He 
developed proteinuria of 0.2 g/24 h ten years 
later, which remained stable. A renal biopsy with- 
out electron microscopy revealed unspecified 
changes, probably secondary to nephroangio-
sclerosis. The patient did not develop chronic 
kidney disease or visual or auditory inpair- 
ment.
His father was diagnosed with chronic kidney 
disease at 75, with creatinine clearance around 
30-40 ml/min with proteinuria (0.1 g/24 h) and 
haematuria. He had suffered from arterial 
hypertension and high tones sensorineural 
Figure 3. Genetic sequence of the 
IVS3 + 1G > C mutation and pos-
sible changes in the resultant pro-
tein: A. Initial sequence of the pro-
tein COL4A4 in normal conditions. 
B. COL4A4 protein sequence with-
out exon 3. C. COL4A4 protein se-
cuence with intron 3.
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when he was one year old and, like his sister 
did not show any visual impairment.
The mother of both patients suffered from 
microhematuria, non-nephrotic proteinuria, 
arterial hypertension, grade III chronic kidney 
disease and sensorineural hearing loss since 
adolescence. The patient’s maternal great-
grandfather died when he was 20 years old. He 
suffered from sensorineural hearing loss and 
chronic kidney disease, as did his two daugh-
ters (the patient’s grandmother and aunt). The 
existence of hematuria, proteinuria or ocular 
impairment in these patients could not be 
determined because they had all passed away.
The family data suggested the existence of 
ADAS, but we could not find any pathogenic 
mutation after sequencing 21 exons of the 
COL4A4 gene.
Besides the two new pathogenic mutations, we 
have also found seven new intron variants 
(Table 3) in the different families. These vari-
ants are also present in healthy controls.
Discussion
In our work, we have searched pathogenic 
mutations in COL4A4 gene in families with phe-
notypic signs of ARAS, ADAS and TBMN, which 
had a previous diagnosis of absence of muta-
tions in COL4A3 gene. 
hearing loss from the age of 79. He did not 
show visual impairment.
The paternal family had a significant history of 
sensorineural hearing loss, as can be seen in 
the family tree. These patients could not be 
studied to determine the presence of other 
components of AS, as some of them had 
already passed away and others did not live in 
the city where the study was conducted.
The data of this family suggested the presence 
of ADAS. We found, in COL4A4 gene, the muta-
tion IVS3 + 1G > C (c.192 + 1C in HGVS nomen-
clature) which had not been previously 
described. It should be considered pathogenic 
since the canonical sequence in RNA is affect-
ed. The absence of RNA prevented us from per-
forming a functional study. However, the index 
case’s brother who had no AS symptoms did 
not have it. 
Sixth family: The index case was a 41-year-old 
woman who had her first episode of macrohe-
maturia when she was 3 years old, after a ton-
sillar infection. From that time on, she suffered 
almost constantly from microhematuria, with 
episodes of macrohematuria due to different 
kinds of infections. At the age of 6, proteinuria 
of 0.35 g/24 h was diagnosed, which increased 
progressively until nephrotic range at 36 years 
old. A renal biopsy was performed at 22 years 
old, which showed the lamination of the 
glomerular basement membrane.
She developed arterial hypertension and 
chronic kidney disease when she was 
pregnant (aged 36) which evolved rapidly 
and she was included in a hemodialysis 
program 3 years later. 
The presence of high tones sensorineural 
hearing loss was established when she 
was 8 years old. She never showed any 
ocular impairment. Her brother was a 
33-year-old who had had macrohematu-
ria and nephrotic range proteinuria from 
the age of 9 months. He developed 
chronic kidney disease at 14 with a pro-
gressive worsening of his creatinine 
clearance. He began a program of perito-
neal dialysis 5 years later. He never 
underwent renal biopsy. He was diag-
nosed with sensorineural hearing loss 
Table 3. Mutations found in our patients
Mutation Meaning Bibliography Families
IVS 3 + 1 G > C Splicing This work 5
IVS10-39 T > C Polimorfism This work 2
IVS 12-58 A > G Polimorfism This work 4
IVS 12 + 30 G > A Polimorfism This work 3
IVS 17 + 24 A > T Polimorfism This work 6
IVS 19 + 21 C > A Polimorfism This work 4
IVS 37-61 G > T Polimorfism This work 2
IVS 38 + 40 C > A Polimorfism This work 2
c.3011C > T; p.P1004L Polimorfism [8] 6
c.3594G > A; p.G1198G Polimorfism [15] 1
c.3684G > A; p.K1228K Polimorfism [16] 1
c.3979G > A; p.V1327M Polimorfism [17] 1
c.4080G > A; p.P1360P Polimorfism [11] 1
c.4207T > C; p.S1403P Polimorfism [8] 5, 6
c.4267C > T; p.P1423S Missense This work 3
c.4932C > T; p.F1644F Polimorfism [17] 4, 5, 6
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The study of family 3 led us to the discovery of 
a missense mutation, not yet described. 
Mutation c.4267C > T; pP1423S involves the 
change of a proline by a serine in a region in 
which there has been no specific protein 
domain described (Figure 2). However, the α4 
chain has 26 sequences Gly-Xaa-Yaa, wherein 
Xaa and Yaa is often proline or hydroxyproline. 
This confers flexibility to the protein [8]. Proline 
1423 is located in a sequence Glycine-Valine-
Proline. So this change could reduce that 
flexibility. 
Although it was not possible to perform a func-
tional study (due to the lack of availability in our 
laboratory) we can, however, speculate, from 
the population study in silico data and family 
segregation, that there is a high probability that 
this is the causative mutation of ADAS in this 
family.
The phenotype caused by this mutation is 
variable, since some members have mild 
disease (hearing loss and mild impairment of 
renal function) and other relatives have an 
aggressive form, with the need for renal 
replacement therapy early in life. The possible 
reason for this phenotypic heterogeneity may 
be the presence of pathogenic mutations in 
genes encoding other proteins of the glomeru-
lar basement membrane (integrins, metallopro-
tease, Laminins or podocin), and, by modulat-
ing the COL4A4 mutation, promote the onset of 
the kidney impairment [9, 10]. 
In family 5 (who suffer from ADAS) a mutation in 
intron 3 of the COL4A4 gene was found. 
Although most of the mutations described so 
far in the COL4A3 and COL4A4 genes are mis-
sense mutations, intronic mutations that modi-
fy the RNA maturation (splicing) have also been 
described [11]. The mutation IVS3 + 1G > C of 
the COL4A4 gene changes RNA processing, 
which affects a canonical sequence process-
ing. The absence of RNA from the proband pre-
vented us from determining whether the muta-
tion involves the incorporation of intron 3 or 
loss of exon 3 in the coding sequence. 
Regardless, a change in the reading frame and 
a premature stop codon, which would produce 
a protein unable of adequately trimerizing, 
would likely occur. Figure 3 shows the reading 
phase change if exon 3 is lost, and the prema-
ture stop codon that is produced in the case of 
the inclusion of intron 3 in RNA, which gener-
ates a truncated protein.
In this family, the mutation generates a mild 
phenotype, in which chronic kidney disease 
appears at an advanced age and there is no 
development to end stage chronic kidney dis-
ease. This phenotype coincides with the one 
traditionally described for ADAS [1, 2].
The main limitation of our study is that the tech-
nique used to detect mutations (PCR amplifica-
tion of all exons, detection of changes in their 
electrophoretic mobility in heteroduplex and 
sequencyng these exons) does not detect 
100% of mutations [12]. This fact could explain 
why in families 2 and 6, with a clear clinic diag-
nosis of ARAS and ADAS, no pathogenic muta-
tion was detected. 
However, in families 1 and 4, this lack of diag-
nosis may be due to the technique’s shortcom-
ings or because of other diseases that may 
present with similar symptoms.
Family 1 had the diagnostic of TBMN, and only 
40% of patients with this disease are heterozy-
gous carriers of mutations in genes COL4A3/
A4 [6], but the remaining members do not pres-
ent any impairment in these genes. It has 
recently been reported that mutations in the 
CFHR5 gene, which encodes a complement 
protein, are associated with glomerulopathy 
with haematuria and risk of progressing to 
chronic kidney disease [13]. 
In the index case of family 4, the absence of 
COL4A3/COL4A4 gene mutations may also be 
related to a different clinical entity than AS. 
Macrothrombocytopenia has been associated 
with microhematuria, secondary to mutations 
in the MYH9 gene. There are three clinical enti-
ties: the May-Hegglin, Fechtner and Epstein 
syndromes, which share ultrastructural lesions 
with AS [14] and may be associated with hear-
ing impairment and mimic this syndrome. 
The seven undescribed intronic variants detect-
ed have been considered as population poly-
morphisms, because they are located in intron-
ic regions, far from the splicing sites, which are 
shared by different families, as well as from 
randomly selected healthy individuals.
Conclusions
We describe two new pathogenic mutations 
in the COL4A4 gene, responsible for autoso- 
mal dominant Alport syndrome and 7 new 
intronic variants, considered as demographic 
polymorphisms.
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Genetic diagnosis of autosomal Alport syn-
drome is hampered by the large presence of 
polymorphisms [8, 15-17] (both in the exons 
and in the intronic regions), and by the possibil-
ity that other genes are involved in generating 
very similar clinical syndromes. 
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Table S1. Primers and amplification conditions of the 
COL4A4 gene 
Exon Secuency 5’-3 Anealing Temperature Size
2F TCTGGAAGAGAAGACTGGCA 55°C 152 pb
2R AAGCAGGCAATCACACTGA
3F TGTTTAAATTAATCTGCGTT 52°C 105 pb
3R GCAACCAGAGCTAGTG
4F CGATGAGTACTGGTATACTA 55°C 152 pb
4R ATGCTGCCCATGTTGGTCTT
5F ACCCCCATTTCTTTTTAATC 55°C 208 pb
5R GGTGAGTCTTTCATGTGAAT
6F TCTCTTTGTTTTATTTTCTG 50°C 127 pb
6R GATGAGTACTTCTGCCTTTT
7F TTTCGCAAAAATGCTTCACT 55°C 211 pb
7R CCACAGGGCCTGTTCACTTA
8F TACTGAAATGGTAATACGCT 55°C 184 pb
8R CATGGGCTTACCTATTTGGA
9F TGTGTGGACTTAAAGCGATG 51°C 96 pb
9R TAGAGCCTGCTCAGGAGACT
10F TTGGGTAACAGATGCACTGA 55°C 129 pb
10R AAGGGATCACATCAGCAGTG
11F TTGTGTTTTTTTCTCCCTTG 49°C 110 pb
11R TTTCATTGTTCAGGGCTCTA
12F AGCCAGAAGTCTTAATTGCT 55°C 156 pb
12R TCACCATTTGCTCCTCAGAG
13F GGGTGGAAACCTTCAAAACA 55°C 179 pb
13R TACTTTCCAAGGTGACATAT
14F GGAGATGGAATTCAGTATGT 55°C 198 pb
14R AAAGACCATGAGAAATAACA
**
15F CCCCTCTAAATGTTGTCATC 57°C 180 pb
15R TTTGAGCTTGTGGGACTACT
16F AATGATGCACTGAGCTGGTT 57°C 201 pb
16R GCACGCAACAGTACAACTTC
17F ATTTGTCACCCCGTCACTTT 57°C 200 pb
17R GAATGATTCCTGGCAATACT
18F CCAGGCAACATGAGTAAAAT 55°C 155 pb
18R TGGAGGAACTGAATAGGAAC
**
19F TGCACATACCATTTGTTTAT 55°C 175 pb
19R CCAGGGCACATCAGGGCATC
**
20F TTCTTCTACAGAGACGTTT 50°C 259 pb
20R TGCTAATGGATATGAATAAG
21F TATAGAAGACAGTCAGAAAA 50°C 181 pb
21R TAGAAATTCTACCTTTGGTG
22F AAATATGACAAATCTGCCAT 55°C 227 pb
22R GGAAAGATGACTGGTAAGAG
**
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23F TGATCCATCACAATTAACCT 51°C 149 pb
23R CAGGGAGTTAAGTGATTGAT
24F ACTTTACCCTCTGCTGATAA 55°C 227 pb
24R GGGAAATAGTTGTTTGTATG
**
25F GACATTCAGTGGTTGGTAAT 55°C 281 pb
25R TAAACACTTGTACCCCAAAG
**
26F TCAGTTATGTGAATGCCGCT 51°C 146 pb
26R TGGGAAGTATATAAGACAGT
27F TGAGTCTGTGTTTTGTTTTT 47°C 161 pb
27R AAAAAAAAAAACCTCAC
**
28F ATTGGTTCTATACTTGCACA 55°C 309 pb
28R TCTATGCACCAAAAGGACAG
**
29F TGGGCCATCTGTATAGTTTT 52°C 269 pb
29R TAATAGTAAGTAGGGTAAGC
30F GCCTTCACACACTGTGGTCA 55°C 240 pb
30R ATGGGAGGACATCATGGAAA
*, **
31F TCCTAAAACTTTATGCTCTC 50°C 221 pb
31R TCAAATACCAGAAACAAATG
32F CCTGTTCATTTTGTTCTTGC 52°C 187 pb
32R TGTCAACTTATTTGATATGG
33F TTTCAGCAGAGACCTGTAAC 52°C 271 pb
33R AAGAACAGAAAGGTTTTATT
34F GTTGTGCATGTGCCATTTGT 55°C 154 pb
34R GATGGCTTCTGTATCTCC
35F TGAGACCAAATTAAATTGTC 55°C 211 pb
35R TCATTGCCAGCTAGAAGTAA
36F CAAACGGCAACTCTGATGTT 52°C 183 pb
36R AGTGCTCAGGAAGTCTCCAG
37F TATCTGGCCATCTGCAAAAC 55°C 173 pb
37R TTGTGGGATGGGCTTCATTT
38F GCGTTTGTGGCTAGAGTGAG 55°C 189 pb
38R GAACCATGGACTGAAGCTCAG
39F AGGCACTATAACAGGGACAAA 54°C 420 pb
39R CATCCTTTGTCATGATTCTCTC
40F ACCTTCCAAATGCAATGAGG 52°C 184 pb
40R CATCCTTTGTCATGATTCTCTC
41F TTTTTGTCTCTTCTCTGTGG 42°C 218 pb
41R AGTTATTCACATATTACTTA
*
42F GCCCTCATTTTTATGTTTTG 52°C 189 pb
42R GTTGGAAGCTCACCTGGAAG
43F GACTGGCCTCGTTTG 49°C 178 pb
43R TTAATATCCTTACAGCACCC
44F ATTACACAAGCGGTGATTCC 54°C 213 pb
44R AGAATTTCATTTCAGCAATA
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45F CACCAGCATCATAAACTT 49°C 186 pb
45R AGGTTTACAGTGTCAGAGAA
46F AGTGCCAGAACAGAGGTGCT 55°C 297 pb
46R GGAGATGGGCGATCCTGTA
47F ACACCAGCTGTCTCTTCTTC 55°C 353 pb
47R TGAATGAGCCAGGGTTT
48F GTGTGTGTCTGAGCCCTAAT 55°C 323 pb
48R TGGTGAATTTCGCATTCT
Investigators: Consolación Rosado, Elena Bueno, Rogelio González-Sarmien-
to. In this table we show the amplification conditions of the primers of the 
COL4A4 gene in our laboratory. *0.5 mL MgCl2 **0.3 mL DMSO.
